From Style to Spotlight: Celeste Moore and Luxn Team Up to Transform On-Camera Presence for Elite Media Clients

Austin, TX – Two powerful forces in media and personal branding—Celeste Moore of Moore Style and James Luctamar of Luxn—have joined together in a strategic partnership that promises to redefine how public figures prepare for high-stakes media visibility. This collaboration pairs luxury image consulting with elite-level media placement to serve entrepreneurs, CEOs, executives, authors, speakers, and influencers who are stepping into national and international spotlight opportunities.

Visibility is currency—but true influence comes not just from being seen, but from being remembered. That’s where this partnership stands apart. Luxn specializes in securing high-profile media opportunities for its clients, including television interviews, podcast features, and print coverage in top-tier publications. Moore Style, on the other hand, ensures that once clients land those coveted moments, they are prepared to look the part, feel confident, and embody the message they’re there to deliver.

This full-spectrum service gives clients an edge by combining strategic public relations with personal brand presentation. Together, Celeste Moore and James Luctamar now offer a seamless bridge between visibility and presence, creating unmatched value for clients in competitive industries.

Clients referred by Luxn will now receive a complimentary image consultation with Celeste Moore, which includes:

  • Refined On-Camera Image Strategy – Tailored insights to ensure your visual presentation aligns seamlessly with your personal brand and media message.

  • Signature Styling Enhancements – Expert guidance on high-impact wardrobe choices that boost presence, authority, and memorability in interviews and public appearances.

  • Credibility-Driven Visual Planning – A fast-track roadmap to help you visually communicate trust, expertise, and alignment with your next-level identity—whether you’re stepping onto a stage, screen, or into a high-stakes boardroom.

Celeste Moore works with high-performing individuals across industries—from visionary entrepreneurs to corporate leaders and rising authors. Her clients are often in the process of launching a book, stepping into speaking circuits, expanding their brand through thought leadership, or preparing for high-level investor and media relations. Each consultation is personalized to meet the unique goals of the individual, ensuring they show up fully aligned with their next-level identity.

Luxn, under the leadership of James Luctamar, represents a new wave of PR strategy—where placement is intentional, outcomes are high-converting, and clients are not just featured, but positioned. Luxn has secured press placements and interviews for founders, product creators, industry disruptors, and service-based professionals in competitive sectors like tech, finance, health and wellness, entertainment, and entrepreneurship.

This partnership is particularly suited for individuals:

  • Preparing for television and digital media interviews

  • Booking podcast appearances and conference stages

  • Releasing a book, product launch, or rebrand

  • Seeking investor attention or entering high-visibility roles

  • Looking to position themselves as trusted authorities and public figures

The alignment between Luxn’s visibility engine and Celeste’s transformation process creates a unified path for clients who don’t just want to be seen—they want to own the room, influence perception, and elevate their long-term brand equity.

Both Moore Style and Luxn are accepting a limited number of partnership clients under this new initiative. The services are now live and available to existing and new clients of Luxn.

About Celeste Moore

Celeste Moore is a Global Certified Master Image Consultant, Celebrity Stylist, and Luxury Personal Branding Expert with over 18 years of experience. She has worked with entrepreneurs, C-suite executives, media personalities, and high-profile individuals to align their visual identity with their personal mission. Celeste has been featured at New York Fashion Week and is the host of Moore Style, a podcast for visionaries, leaders, and game-changers. Her work focuses on color psychology, silhouette mastery, and media-ready styling.

Website: www.celestemoore.com

About Luxn

Luxn is a premier PR and media placement firm that specializes in helping thought leaders secure top-tier visibility. Founded by James Luctamar, Luxn has developed a reputation for delivering high-impact press placements and media appearances that help clients build authority, attract aligned opportunities, and accelerate credibility. Luxn works across industries including entrepreneurship, health, wealth, innovation, and media.

Website: www.luxn.com

Media Contact
Contact Person: Celeste Moore
Email: Send Email
Phone: 5122008794
Country: United States
Website: https://celestemoore.com/

Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko

The Key Urothelial Carcinoma Companies in the market include – Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others.

 

DelveInsight’s “Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Urothelial Carcinoma, historical and forecasted epidemiology as well as the Urothelial Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Urothelial Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Urothelial Carcinoma Market Forecast

 

Some of the key facts of the Urothelial Carcinoma Market Report:

  • The Urothelial Carcinoma market size was valued ~USD 900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2025, Phase I findings for SHR-A2102 in individuals with advanced or metastatic urothelial carcinoma were presented at the 2025 ASCO Genitourinary Cancers Symposium.

  • In December 2024, China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd. ‘s SHR-A2102 has been proposed for designation as a breakthrough therapy. The drug is intended as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma who have not responded to prior platinum-based chemotherapy and PD-(L)1 inhibitor treatment.

  • In September 2024, The Phase II findings for BL-B01D1 were shared during the 2024 ESMO Congress, highlighting its initial efficacy and safety in patients with locally advanced or metastatic urothelial carcinoma who had received prior treatments.

  • In August 2024, Mabwell Therapeutics, a biopharmaceutical company based in the US, has received authorization from China’s National Medical Products Administration (NMPA) to initiate a Phase III clinical trial of 9MW2821 in combination with Toripalimab for the treatment of urothelial carcinoma. This randomized, open-label study will compare the effectiveness of 9MW2821 plus Toripalimab against the investigator’s selected chemotherapy as a first-line treatment for patients with locally advanced or metastatic urothelial carcinoma.

  • During the forecast period (2024–2034), pipeline candidates like enfortumab vedotin+pembrolizumab±cisplatin/carboplatin, erdafitinib+cetrelimab, and durvalumab+SoC (cisplatin+gemcitabine/carboplatin+gemcitabine)±Tremelimumab are expected to contribute to the growth of the UCC market size.

  • In 2023, the United States held the largest share of the UCC market in the 7MM, representing nearly 70% of the market size compared to the EU4, the UK, and Japan.

  • In 2023, the United States reported the highest number of incident UCC cases, representing approximately 40% of the total global cases.

  • Among the EU4 and the UK, Germany had the highest number of UCC cases, followed by Italy, while the UK reported the fewest cases.

  • Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

  • Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

  • The Urothelial Carcinoma epidemiology based on gender analyzed that Urothelial carcinoma in males has two-to-three fold greater incidence as compared to females

  • The Urothelial Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Urothelial Carcinoma pipeline products will significantly revolutionize the Urothelial Carcinoma market dynamics.

 

Urothelial Carcinoma Overview

When the cells that make up the urinary bladder develop into cancer, urothelial carcinoma begins. Any of the four bladder wall layers can give birth to bladder neoplasms. Over 95% of them are considered to be epithelial, while the remaining 5% are non-epithelial (mesenchymal). Urinary carcinomas are epithelial tumors that have differentiated towards normal urothelium.

 

Get a Free sample for the Urothelial Carcinoma Market Report:

https://www.delveinsight.com/report-store/urothelial-carcinoma-market

 

Urothelial Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Urothelial Carcinoma Epidemiology Segmentation:

The Urothelial Carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Urothelial Carcinoma

  • Prevalent Cases of Urothelial Carcinoma by severity

  • Gender-specific Prevalence of Urothelial Carcinoma

  • Diagnosed Cases of Episodic and Chronic Urothelial Carcinoma

 

Download the report to understand which factors are driving Urothelial Carcinoma epidemiology trends @ Urothelial Carcinoma Epidemiology Forecast

 

Urothelial Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urothelial Carcinoma market or expected to get launched during the study period. The analysis covers Urothelial Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Urothelial Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Urothelial Carcinoma Therapies and Key Companies

  • KEYTRUDA (pembrolizumab): Merck

  • OPDIVO (nivolumab): Bristol Myers Squibb

  • BT8009: Bicycle Therapeutics

  • Eganelisib + Opdivo: Infinity

  • Infigratinib: QED Therapeutics

  • Tislelizumab: BeiGene

  • Cyramza: Eli Lilly

  • Tecentriq: Roche

  • UGN-102: UroGen

  • Bempegaldesleukin: NektarTherapeutics /BMS

  • Pemazyre (Pemigatinib): Incyte

  • ABSK091/AZD4547: Abbisko

  • Selinexor: Mamta Parikh

  • Tremelimumab: AstraZeneca

  • Erdafitinib: Janssen Research & Development, LLC

  • Niraparib: Pfizer

  • Atezolizumab: Inovio Pharmaceuticals

  • Atezolizumab: Hoffmann-La Roche

  • RC48-ADC: RemeGen Co., Ltd.

 

Discover more about therapies set to grab major Urothelial Carcinoma market share @ Urothelial Carcinoma Treatment Market

 

Urothelial Carcinoma Market Strengths

  • Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of advanced UC market

  • Strong pipeline activity with potential phase III and phase II emerging therapies

  • Presence of several approved therapies for the treatment of urothelial carcinoma patients.

 

Urothelial Carcinoma Market Opportunities

  • Rising incidence of cancer will provide the larger window of opportunity for new treatments

  • Reoccurrence is very common in cancers even after proper treatment. This opens up new window for pipeline activity

  • Increase in awareness and research of the indication, which provides a clearer aspect regarding potential options for treatment that can be explored by the key players

 

Scope of the Urothelial Carcinoma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Urothelial Carcinoma Companies: Merck, Bristol Myers Squibb, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics /BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

  • Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

  • Urothelial Carcinoma Therapeutic Assessment: Urothelial Carcinoma current marketed and Urothelial Carcinoma emerging therapies

  • Urothelial Carcinoma Market Dynamics: Urothelial Carcinoma market drivers and Urothelial Carcinoma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Urothelial Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Urothelial Carcinoma Market Access and Reimbursement

 

To know more about Urothelial Carcinoma companies working in the treatment market, visit @ Urothelial Carcinoma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Urothelial Carcinoma Market Report Introduction

2. Executive Summary for Urothelial Carcinoma

3. SWOT analysis of Urothelial Carcinoma

4. Urothelial Carcinoma Patient Share (%) Overview at a Glance

5. Urothelial Carcinoma Market Overview at a Glance

6. Urothelial Carcinoma Disease Background and Overview

7. Urothelial Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Urothelial Carcinoma

9. Urothelial Carcinoma Current Treatment and Medical Practices

10. Urothelial Carcinoma Unmet Needs

11. Urothelial Carcinoma Emerging Therapies

12. Urothelial Carcinoma Market Outlook

13. Country-Wise Urothelial Carcinoma Market Analysis (2020–2034)

14. Urothelial Carcinoma Market Access and Reimbursement of Therapies

15. Urothelial Carcinoma Market Drivers

16. Urothelial Carcinoma Market Barriers

17. Urothelial Carcinoma Appendix

18. Urothelial Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko

The Winslow Hosts Ultimate Eurovision 2025 Song Contest Grand Finale Watch Party in NYC

The Winslow Hosts Ultimate Eurovision 2025 Song Contest Grand Finale Watch Party in NYC
The Winslow, Manhattan’s premier British-inspired gin bar, announces its highly anticipated Eurovision 2025 Song Contest Grand Finale Watch Party on Saturday, May 17, 2025. Located at 243 East 14th Street, The Winslow offers Eurovision enthusiasts the perfect venue to experience Europe’s most celebrated music competition without leaving New York City.

NEW YORK, NY – May 8th, 2025 – The Winslow, Manhattan’s premier British-inspired gin bar, announces its highly anticipated Eurovision 2025 Song Contest Grand Finale Watch Party on Saturday, May 17, 2025. Located at 243 East 14th Street, The Winslow offers Eurovision enthusiasts the perfect venue to experience Europe’s most celebrated music competition without leaving New York City.

The Eurovision Song Contest, now in its 69th year, will broadcast live from Basel, Switzerland. The Winslow’s Eurovision 2025 watch party transforms the East Village establishment into a mini-Europe, complete with country-themed gin cocktails, Eurovision bingo, and multiple viewing screens throughout the venue.

“Eurovision combines spectacular performances, cultural diversity, and friendly competition—elements that perfectly align with The Winslow’s community-focused atmosphere,” says Mark Tafoya, Managing Partner at The Winslow. “Our annual watch party has become a tradition for both dedicated Eurovision fans and curious newcomers looking to experience this international phenomenon.”

The event features Eurovision-inspired specialty cocktails named after iconic past winners, themed food offerings, and interactive activities including live voting and Eurovision bingo. Multiple screens and a professional sound system ensure guests won’t miss a single performance or dramatic vote reveal.

This year’s Eurovision Grand Final includes automatic qualifiers Switzerland (host nation) with Zoë Më performing “Voyage,” France’s Louane with “Maman,” Germany’s sibling duo Abor & Tynna presenting “Baller,” Italy’s Lucio Corsi performing “Volevo essere un duro,” Spain’s Melody with “Esa diva,” and the United Kingdom’s Remember Monday performing “What the Hell Just Happened?”

The Winslow has established itself as New York City’s premier destination for Eurovision celebrations, drawing diverse crowds including European expats eager to cheer on their home countries. The electric atmosphere recreates the excitement of being in the Eurovision arena, with attendees often arriving in Eurovision-inspired attire complete with country flags and festive accessories.

“Our Eurovision watch party embodies what The Winslow stands for—bringing people together through shared experiences, exceptional drinks, and genuine hospitality,” adds Tafoya. “Whether identifying as a longtime Eurovision devotee or simply seeking an entertaining cultural experience, everyone finds their place at our celebration.”

The Eurovision 2025 Song Contest Grand Finale Watch Party at The Winslow begins at 3:00 PM EDT on Saturday, May 17, 2025.

About The Winslow

The Winslow is a British-inspired gin bar and eatery located in New York City’s East Village. Offering over 40 hand-selected gins, craft cocktails, and British-influenced cuisine, The Winslow creates an authentic yet innovative hospitality experience. The establishment serves as a community hub for international sports viewing, cultural celebrations, and private events. Where gin meets good times.

Contact Information

For more information, please contact Mark Tafoya at https://thewinslownyc.com/.

Phone: 212-777-7717, Address: 243 East 14th Street, New York, NY 10003

Media Contact
Company Name: The Winslow
Contact Person: Mark Tafoya
Email: Send Email
Phone: (212) 777-7717
Address:243 E 14th St
City: New York
State: NY
Country: United States
Website: https://thewinslownyc.com/

Designed | Curated Interiors Featured on Redfin for Elevating Sacramento Homes with Timeless Design

Designed | Curated Interiors Featured on Redfin for Elevating Sacramento Homes with Timeless Design

Amy, principal interior designer at Designed | Curated Interiors.
Redfin showcases Designed | Curated Interiors for transforming Sacramento spaces with thoughtful and elegant design solutions

Sacramento, CA – May 8, 2025 – Designed | Curated Interiors, a top-rated interior design Sacramento studio, is proud to announce its recent feature on Redfin, a nationally recognized real estate platform. The spotlight underscores the studio’s dedication to crafting beautiful, livable spaces tailored to each client’s personality and lifestyle.

Founded by Amy, an experienced interior designer Sacramento professional with a marketing background, the studio brings a distinctive edge to the design scene in Northern California. Her unique approach combines storytelling, function, and timeless aesthetics across residential homes, vacation properties, and new builds.

Redfin’s feature applauds Amy’s ability to seamlessly blend modern comfort with classic design. Her range of services includes kitchen and bath renovations, full-home design, and accessible spaces certified through Universal Design and Design4Life credentials.

Clients consistently celebrate Amy’s professionalism, attention to detail, and stress-free process. Her designs not only enhance homes visually but also improve functionality—making them more enjoyable and efficient for everyday living. With a growing presence in Sacramento and Folsom, Amy’s reputation as a trusted design partner continues to flourish.

“Being featured on Redfin validates the work we’re so passionate about,” Amy said. “We aim to create homes that reflect who people are and how they live, not just what’s trending.”

In a region where housing and design trends evolve rapidly, Designed | Curated Interiors remains ahead of the curve, offering solutions that are both timeless and highly practical.

For those seeking to elevate their living space, Amy and her team are ready to deliver a personalized, high-impact design experience.

Media Contact
Company Name: Designed | Curated Interiors
Contact Person: Amy
Email: Send Email
Phone: +1 (916) 756-5977
Country: United States
Website: https://www.designedcurated.com/

Confessions Wraps Filming: A Collision of Human Darkness and Eastern Philosophical Aesthetics, Elevating Chinese Drama to New Heights

Following the success of The Pig, The Snake, and The Pigeon, which became a dark horse hit, director Ching-Po Wong reunites with lead actors Ethan Juan, Gingle Wang, and the original team to create a new psychological thriller, Confessions. After 120 days of shooting, the film officially wrapped on May 3, and a media conference for Confessions was held at The Red House. During the event, the host Bowie Tsang led the press conference, where the entire creative team and main cast, including Ethan Juan, Gingle Wang, Alyssa Chia, Yi-Wen Chen, Vivian Sung, Shih-ling Hsueh, Nikki Hsieh, Peggy Tseng, Chuan-Chen Yeh,Ben Yuen, Frederick Lee, Tracy Chou, Han Chang, Sean Lin and Troy Liu, made their appearances. The team revealed the first glimpse of Confessions and shared behind-the-scenes stories about the production. On May 8, the series also released its official 2025 Youku Spring Poster, themed “Under the Surface”, showcasing a powerful portrayal of the fissures in human nature. The series is reportedly set to be introduced to mainland China by Youhug Media and Youku, and exclusively streamed on Youku. Blending Eastern philosophical aesthetics with the universal resonance of the abyss of human nature, Confessions aims to redefine the psychological suspense genre and reach new heights for Chinese dramas.

The press conference was meticulously crafted by the powerhouse production team behind Confessions. Two-time Golden Horse Award-winning art director Shuo-lin Liang oversaw the event’s visual design, featuring exposed tree roots and ambient jungle sounds that echoed the drama’s key settings. The floor, inspired by Mondrian’s signature red, yellow, and blue geometric elements, created a visually abstract atmosphere. Renowned director of photography Chi-Wa Lee, known for his work on Kar-wai Wong’s The Grandmaster, led the visual direction for both the series and the event. Chris Hou- winner of Golden Bell, Golden Melody, and Golden Horse Awards served as music director, while still photographer Cheng-Chang Kuo captured the event’s most striking moments. According to reports, the series was meticulously prepared over four months, with multiple script revisions, location scouting, and casting efforts. The shooting intensity and complexity far exceeded that of The Pig, The Snake, and The Pigeon, aiming to present the truth hidden in silence with unparalleled detail.

e6f35e12778886b8b91c1864bdfa8f74

First Concept Trailer Released: Stark Lighting and Suffocating Sound Effects Intertwine

At the press conference, the “Destined Suspense” trailer was unveiled for the first time. The story begins with a bombing and kidnapping case in Taipei in 2004- an incident that entwines the fates of three unrelated families and sets off two decades of intergenerational conflict. The teaser opens with a close-up of Golden Horse Best Actor Ethan Juan, his eyes brimming with confusion and unshed tears. It then cuts to Taipei Film Awards Best Actress Gingle Wang, her blood-streaked face twisted in an eerie smile. One by one, the ensemble cast is introduced: Golden Bell Best Actor Shih-Ling Hsueh, Golden Horse winner Nikki Hsieh, Golden Horse Best Actor Yi-Wen Chen, Golden Horse Best Actress Alyssa Chia, Taipei Film Awards Best Actor Joseph Chang, and Golden Horse nominee Vivian Sung. With intense, unsettling expressions, they each reflect on the theme of “trees” as a metaphor for hatred. The tension culminates with Ethan Juan’s haunting line- “What madness lies in us to believe this broken world is anything close to normal?”- followed by Gingle Wang aiming a gun in fury, leaving viewers on edge and eager for more.

The “Destined Suspense” teaser adopts a highly stylized audiovisual language to evoke a tense and oppressive atmosphere. Repeated close-ups of eyes and stark lighting ripple through suffocating sound design, revealing the characters’ psychological fractures amid intertwined fates and inherited trauma. It portrays an intense moral showdown between two generations caught in deep-seated family feuds and a web of interwoven destinies across multiple households. Viewers are drawn toward the hidden truths lurking beneath the silence- and the abyss of human nature. The creative team aims to heighten emotional tension through psychological thriller techniques, subverting perspective and sensory expectations, and turning viewers into active “co-conspirators” in the search for truth.

Creative Roundtable: The Fusion of Violent Aesthetics and Social Human Nature Suspense

Actor Breakthrough: The Ultimate Interpretation of Human Psychological Fractures

Confessions is not only crafted by the same team behind The Pig, The Snake, and The Pigeon but also continues the legacy of its predecessor’s “violent aesthetics and philosophical musings.” It incorporates elements of social suspense, delving into psychological themes such as the trauma of dysfunctional families and ethical dilemmas, while intensifying the narrative with a focus on social issues. The cast- including Ethan Juan, Gingle Wang, Alyssa Chia, Yi-Wen Chen, Vivian Sung, Shih-ling Hsueh, Nikki Hsieh, Peggy Tseng, Chuan-Chen Yeh, Ben Yuen, Frederick Lee, and Troy Liu- also took the stage at the press conference to share their reflections on filming and offer deep insights into the psychological complexity of their characters.

The first to speak was Ethan Juan, who plays the male lead San Lin. He revealed that the character’s complex emotional journey resonated deeply with his own life experience- he felt as if he had stepped into San Lin’s shoes, simultaneously portraying another life and making a personal choice in the process.

Gingle Wang, who plays the female lead, followed by sharing that she portrays four different characters in the series- a major milestone in her acting career. To fully embody each role, she took a specially designed voice training course to craft distinct traits for each persona.

Alyssa Chia, who plays forensic psychologist Xin Hu, expressed her admiration for the lead actors’ interpretations and noted that her own role centers on witnessing humanity and seeking redemption of the soul. She admitted feeling emotionally stifled at times due to the character’s unspoken inner struggles.

Other cast members then spoke in turn, offering reflections on their roles and creative experiences. Yi-Wen Chen remarked that Confessions feels closer to real life than The Pig, the Snake and the Pigeon, though both explore themes of good and evil, crime and punishment- this series, he said, offers broader scope and more possibilities. Vivian Sung described her character Yun-jia Xu as unlike any she had played before- a role she would have regretted turning down for the rest of her life.

Shih-ling Hsueh admitted that this was the most mentally exhausting production he’s worked on in recent years- often counting the minutes until wrap. Nikki Hsieh also called the script “absolutely insane,” saying, “I even told my agent to get me any role- I just had to be in this project.” Hong Kong actor Ben Yuen, who made a special trip to attend the event, shared that he filmed several major scenes within just six hours. Though it was intense, he was thrilled to reunite with the director and Yi-Wen Chen. The press conference was charged with energy, and the cast’s heartfelt insights into their characters further heightened audience anticipation for the drama’s suspense-filled storyline.

First Look at Character Stills and Poster | Suspense Captured in Shadows of Love and Hate

Alongside the press event, eight black-and-white character stills were unveiled, each one like a frozen fragment of time and space. Cloaked in stark contrasts of light and shadow, the images hint at the characters’ intricate inner worlds and the suspense lurking beneath the surface. The cast appear solemn, ambiguous, or lost in thought- every subtle expression quietly revealing buried truths and hidden lies. More than just atmospheric, the stills add a layer of mystery to the series, drawing viewers deeper into the psychological tension and compelling them to uncover the truth behind the silence.

The “Under the Surface” themed poster for Confessions was unveiled as part of the 2025 Youku Spring release. The poster features a distinctive black-and-white aesthetic, contrasted by the bold red title, creating a sense of suspenseful rebirth and mystery. Across the two versions of the poster, the lead characters appear with different expressions- either in a scream, a vacant stare, or deep thought- conveying the psychological turmoil they endure and the hidden pain of their pasts. Notably, the two posters mirror one another, seemingly embedded with clues from the storyline. Viewers were quick to comment, saying they had their “8x magnifying glasses ready,” urging the platform to unlock this 20-year psychological showdown.

Looking Ahead: Chinese Drama Steps onto the International Stage with New Horizons

As the press conference drew to a close, Confessions officially entered post-production. Leveraging cross-strait collaboration and a top-tier creative team, the series continues to embrace a fusion of Eastern and Western storytelling. Through refined editing and visual effects, the production aims to transcend linguistic and geographical boundaries, allowing global Chinese-speaking audiences to fully immerse themselves in the series’ exploration of moral dilemmas and the abyss of human nature. Confessions aspires to become a powerful window for Chinese-language storytelling to reach the world stage, showcasing the unique appeal and influence of Chinese drama on the international screen.

Media Contact
Company Name: SHANGHAI YOUHUG MEDIA CO., LTD
Contact Person: CHEN SHU
Email: Send Email
Country: China
Website: http://www.youhugmedia.com

Vascular Dementia Market Growth Projections 2024-2034: DelveInsight Analysis | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP

The Key Vascular Dementia Companies in the market include – Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others.

 

DelveInsight’s “Vascular Dementia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vascular Dementia, historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Vascular Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vascular Dementia Market Forecast

 

Some of the key facts of the Vascular Dementia Market Report:

  • The Vascular Dementia market size was valued approximately USD 2,399 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In March 2025, Hemostemix Inc. (‘Hemostemix’ or ‘HEM’) (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a company specializing in autologous angiogenic stem cell therapies, showcased its ACP-01 treatment for vascular dementia to Wall Street. Having already treated 498 patients for various cardiovascular conditions, the company highlighted ACP-01’s unique ability to stimulate angiogenesis, increase neurotrophic factor expression in the brain, and activate specific chemokines. “These mechanisms strongly indicate ACP-01’s potential as an effective therapy for vascular dementia,” said Dr. Fraser Henderson, Neurosurgeon and Chief Medical Officer of Hemostemix Inc.

  • In September 2024, Vesper Bio has shared results from a Phase I trial of VES001, a potential disease-modifying therapy for frontotemporal dementia (FTD) aimed specifically at patients with progranulin gene mutations (GRN). The company administered the first dose to a participant in the trial last December. The study, which included 78 healthy volunteers, was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic target engagement of VES001.

  • The market size across the 7MM is projected to grow at a CAGR of 4%, driven by heightened disease awareness, improved diagnostics, and the introduction of new therapies.

  • Among European countries, Germany reported the largest market size for Vascular Dementia at approximately USD 136 million in 2023, while Spain had the smallest market size at around USD 74 million.

  • The estimated market size for Vascular Dementia in Japan was approximately USD 480 million in 2023, representing 20% of the total market across the 7MM.

  • In 2023, the total number of prevalent dementia cases in the 7MM was approximately 22 million.

  • In 2023, the total number of diagnosed prevalent cases of vascular dementia in the United States was approximately 1 million.

  • In 2023, the United States had the highest diagnosed prevalent population of vascular dementia, making up about 40% of the total in the 7MM. In comparison, the EU4 and the UK represented approximately 32%, while Japan accounted for around 28% of the overall population share.

  • In 2023, Germany had the highest number of prevalent dementia cases among the EU4 countries, with 1,843 thousand cases, followed by Italy with 1,365 thousand cases. Conversely, Spain reported the lowest number of cases, totaling 934 thousand.

  • In 2023, it was estimated that Japan had approximately 320 thousand diagnosed prevalent cases of vascular dementia, primarily in the 81–90 years age group.

  • DelveInsight estimates indicate that there were about 3 million diagnosed prevalent cases of dementia in Japan in 2023.

  • Key Vascular Dementia Companies: Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others

  • Key Vascular Dementia Therapies: BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others

  • The Vascular Dementia epidemiology based on age-specific cases analyzed that Vascular Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare

  • The Vascular Dementia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vascular Dementia pipeline products will significantly revolutionize the Vascular Dementia market dynamics.

 

Vascular Dementia Overview

Vascular dementia is a type of cognitive decline caused by reduced blood flow to the brain, often due to strokes or small vessel disease. This condition leads to impaired thinking, memory problems, and difficulties with daily activities. Symptoms can vary widely but may include confusion, disorientation, and challenges in planning or organizing tasks. Unlike Alzheimer’s disease, which primarily affects memory, vascular dementia often has a more sudden onset and fluctuating symptoms. Risk factors include high blood pressure, diabetes, and heart disease. Early diagnosis and management of vascular health can help slow progression and improve quality of life.

 

Get a Free sample for the Vascular Dementia Market Report:

https://www.delveinsight.com/report-store/vascular-dementia-market

 

Vascular Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Vascular Dementia Epidemiology Segmentation:

The Vascular Dementia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Vascular Dementia

  • Prevalent Cases of Vascular Dementia by severity

  • Gender-specific Prevalence of Vascular Dementia

  • Diagnosed Cases of Episodic and Chronic Vascular Dementia

 

Download the report to understand which factors are driving Vascular Dementia epidemiology trends @ Vascular Dementia Epidemiology Forecast

 

Vascular Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vascular Dementia market or expected to get launched during the study period. The analysis covers Vascular Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vascular Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Vascular Dementia Therapies and Key Companies

  • BAC: Charsire Biotechnology Corp

  • PNA1: ProNeurogen Therapeutics

  • Apabetalone: Resverlogix

  • CY6463: Cyclerion Therapeutics

  • Butylphthalide soft capsule: CSPC-NBP Pharma

  • galantamine: Johnson & Johnson

  • Prospecta: Materia Medica Holding

  • donepezil hydrochloride (Aricept): Eisai Co., Ltd.

  • SaiLuoTong capsule: Shineway Pharma

  • Akatinol Memantine: Merz Pharma

  • Cerebrolysin: Ever Neuro Pharma GmbH

  • Cilostazol: Zhejiang Otsuka Pharma

  • risperidone: Janssen, LP

  • DatSCAN: GE Healthcare

 

Discover more about therapies set to grab major Vascular Dementia market share @ Vascular Dementia Treatment Market

 

Vascular Dementia Market Strengths

  • The increasing prevalent population in the 7MM is likely to cause an upsurge in treatment need. Consequently, with successful launch of emerging therapies, the market will witness a boost in the upcoming year.

 

Vascular Dementia Market opportunities

  • Medications with better safety and effectiveness, which provide optimum care are the current unmet need of the VaD disease market.

 

Scope of the Vascular Dementia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Vascular Dementia Companies: Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others

  • Key Vascular Dementia Therapies: BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others

  • Vascular Dementia Therapeutic Assessment: Vascular Dementia current marketed and Vascular Dementia emerging therapies

  • Vascular Dementia Market Dynamics: Vascular Dementia market drivers and Vascular Dementia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Vascular Dementia Unmet Needs, KOL’s views, Analyst’s views, Vascular Dementia Market Access and Reimbursement

 

To know more about Vascular Dementia companies working in the treatment market, visit @ Vascular Dementia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Vascular Dementia Market Report Introduction

2. Executive Summary for Vascular Dementia

3. SWOT analysis of Vascular Dementia

4. Vascular Dementia Patient Share (%) Overview at a Glance

5. Vascular Dementia Market Overview at a Glance

6. Vascular Dementia Disease Background and Overview

7. Vascular Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Vascular Dementia

9. Vascular Dementia Current Treatment and Medical Practices

10. Vascular Dementia Unmet Needs

11. Vascular Dementia Emerging Therapies

12. Vascular Dementia Market Outlook

13. Country-Wise Vascular Dementia Market Analysis (2020–2034)

14. Vascular Dementia Market Access and Reimbursement of Therapies

15. Vascular Dementia Market Drivers

16. Vascular Dementia Market Barriers

17. Vascular Dementia Appendix

18. Vascular Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vascular Dementia Market Growth Projections 2024-2034: DelveInsight Analysis | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP

Hydrogen Exchange Appoints Dr. Mayilvelnathan Vivekananthan to Lead India Push and Unlock Regional Hydrogen Opportunities

Masdar City, Abu Dhabi – May 08, 2025 – Hydrogen Exchange Group is pleased to announce the appointment of Dr. Mayilvelnathan Vivekananthan as an Advisor to the Group. In this role, Dr. Vivekananthan will lead Hydrogen Exchange’s development in India and contribute to its international initiatives to accelerate the global hydrogen economy.

With more than 20 years of experience in green hydrogen, renewable energy, and industrial decarbonization, Dr. Mayilvelnathan brings deep technical expertise and strategic insight. He has led large-scale electrolyzer deployments, overseen hydrogen certification and safety assessments, and delivered feasibility studies for green hydrogen and ammonia projects. His work spans public and private sectors, supporting hydrogen adoption across energy, infrastructure, and industry.

“Hydrogen Exchange is building a global, end-to-end ecosystem to accelerate the commercialisation of hydrogen,” said Clayton Kingman, CEO of Hydrogen Exchange Group. “Dr. Mayilvelnathan’s leadership in India, alongside his international project experience, will help align the core enablers of progress technology, regulation, and collaboration across key markets.”

In his role, Dr. Mayilvelnathan will work with stakeholders across the hydrogen value chain, supporting the Group’s efforts to harmonize opportunities, technologies, and capital to drive practical and scalable hydrogen solutions.

“I’m honoured to join Hydrogen Exchange Group at a pivotal moment for the sector,” said Dr.Mayilvelnathan. “I look forward to engaging across the ecosystem—harmonizing stakeholders, technology, and opportunities—to help accelerate the commercialization of hydrogen globally.”

About Hydrogen Exchange Group

Hydrogen Exchange Group is a global hydrogen marketplace and trading exchange that harmonizes capital, technology, and opportunity across all stakeholders to create commercially viable hydrogen projects and ecosystems. Operating across the full hydrogen value chain, the Group supports both early-stage ventures and mature businesses, working with industry leaders, governments, and financiers to enable integrated and scalable clean hydrogen development.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: HX
Contact Person: Admin
Email: Send Email
Country: United States
Website: https://www.hydrogenexchange.io/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hydrogen Exchange Appoints Dr. Mayilvelnathan Vivekananthan to Lead India Push and Unlock Regional Hydrogen Opportunities

AngelGurlMusic: The Rising Indie Artist Taking the Alternative Scene by Storm

AngelGurlMusic: The Rising Indie Artist Taking the Alternative Scene by Storm
Discover the fresh sounds and raw talent of AngelGurlMusic, blending punk, pop, and alternative into a unique mix.

From Barrie, Ontario, AngelGurlMusic, the moniker of Angelica Chartrand, is making waves in the indie music scene with her unique blend of alternative, punk, and pop sensibilities. A true DIY artist, Angelica writes, produces, and distributes her music independently, showcasing not only her creative talent but also her entrepreneurial spirit. Since launching her musical journey in 2023, she has dedicated herself to crafting authentic and relatable music that resonates with listeners. Chartrand also actively manages her social media presence, connecting with fans and sharing insights into her creative process.

AngelGurlMusic’s commitment to transparency sets her apart. She openly shares the evolution of her songs, starting with just the lyrics, inviting her audience to witness the raw, unfiltered beginnings of her art. This intimate approach fosters a strong connection with her fans, who appreciate her honesty and dedication.

Her music is available on all major streaming platforms, including Spotify. Check out her music video on YouTube.

AngelGurlMusic is not just creating music; she is building a movement. With aspirations to become a leading figure in the music industry, she is relentlessly pursuing her goals with passion and determination. Her journey is one of empowerment, creativity, and unwavering dedication to her craft.

Follow and stream her music, and support this young up and coming artist! Share your reviews and help AngelGurlMusic reach new heights.

ABOUT

AngelGurlMusic, the project of Angelica Chartrand, emerged in 2023 after she began songwriting in 2021. Known for sharing the music-making process from its earliest stages, she connects with her audience through raw, unfiltered lyrics. AngelGurlMusic aims to be the next big artist, driven by a passion for creating authentic and relatable music.

LINKS

https://youtu.be/GNwMIC_5wI4?si=EbjLxW_xiYNmRiZq

https://open.spotify.com/artist/6MKfb3t7VWMa3lt7Mrt05y?si=oejRM8zHT5-Eyc_2RxHieA

@angelgurlmusic

https://www.instagram.com/angel_gurlmusic?igsh=MWpkMXd6NzFmNDNrMg==

https://youtube.com/@angelgurlmusic?si=fvWTTlltFfyUwahx

https://x.com/AngelGurlMusic?t=u2AF6WEWNNIDB6p_Vir-yg&s=09

Media Contact
Company Name: Angelica Chartrand
Email: Send Email
Phone: 800-983-1362
City: Barrie
State: ON
Country: Canada
Website: https://youtu.be/GNwMIC_5wI4?si=EbjLxW_xiYNmRiZq

Artificial Intelligence in Cybersecurity Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

“NVIDIA (US), Intel (US), Xilinx Inc. (US), Samsung Electronics Co., Ltd (South Korea), Micron Technology, Inc. (US), IBM Corporation (US), Amazon Web Services, Inc. (US), Microsoft (US), Palo Alto Networks Inc. (US), Trellix (US), CrowdStrike (US), NortonLifeLock (US), Cylance Inc. (US), ThreatMetrix Inc. (US), Securonix Inc. (US), Sift Science (US), Acalvio Technologies (US).”
Artificial Intelligence in Cybersecurity Market by Security Type (Infrastructure (Network, Endpoint, Cloud), Data, Application), Technology (ML, Deep Learning (CNN, GAN), Context-Aware Computing), Application (IAM, DLP, and UTM) – Global Forecast to 2028.

The global AI in cybersecurity market is expected to grow significantly, rising from USD 22.4 billion in 2023 to USD 60.6 billion by 2028, with a compound annual growth rate (CAGR) of 21.9% over the forecast period. This growth is fueled by the rapid adoption of Internet of Things (IoT) technologies and the increasing number of connected devices worldwide. The escalating frequency and complexity of cyber threats, heightened concerns over data security, and the vulnerability of Wi-Fi networks to breaches are also key contributors to this market expansion.

Emerging opportunities include a rising demand for cloud-based cybersecurity solutions, particularly among Small and Medium Enterprises (SMEs), and the expanding use of social media in business operations, which opens new avenues for AI integration in cybersecurity strategies. However, several constraints are impacting market progress. These include AI’s limited effectiveness in addressing zero-day and advanced persistent threats, as well as a growing incidence of insider attacks. Additionally, the market faces challenges such as a shortage of skilled professionals in both AI and cybersecurity, difficulties in integrating AI systems with existing IT infrastructure, and fundamental limitations within current AI technologies used for cybersecurity applications.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220634996

Software segment to account for the largest market size during the forecast period.

Based on the offering segment, software is anticipated to hold the largest market size during the forecast period. Computer systems rely on integrated software to execute intricate operations, synthesizing data from hardware and processing it through AI systems for intelligent responses. The rise of AI in the cybersecurity software market is driven by a surge in security breaches targeting business applications, where hackers aim to access sensitive data. Stricter data privacy policies and regulations contribute to the increasing demand for AI-based cybersecurity solutions, addressing challenges posed by evolving cyber threats. The adoption of cybersecurity solutions is further propelled by the widespread use of connected devices, the BYOD trend in organizations, and the global increase in internet usage, all aimed at mitigating potential risks.

Managed service to account for higher CAGR during the forecast period.

Based on the services, managed services are anticipated to hold the highest CAGR during the forecast period. Managed services are significantly shaping AI in cybersecurity, fostering a proactive defense landscape. AI algorithms in these services enhance real-time threat detection, automating incident responses for swift mitigation. Resource allocation is optimized through AI automation, allowing cybersecurity teams to focus on strategic initiatives. Continuous monitoring and adaptive security measures provide comprehensive coverage against evolving cyber threats. AI-powered risk management analyzes vast datasets, fortifying organizations against potential vulnerabilities. Scalability, flexibility, and predictive analytics empower organizations to anticipate and respond effectively to cyber threats. The strategic insights from AI facilitate informed decision-making, contributing to cost-effective and efficient cybersecurity operations.

Asia Pacific to exhibit the highest CAGR during the forecast period.

The CAGR of Asia Pacific is estimated to be highest during the forecast period. The AI in cybersecurity market in the Asia Pacific is poised for growth, driven by factors such as population rise and government policies. Emerging methodologies such as Machine Learning, IoT, Big Data analytics, and AI are being deployed as organizations shift to the cloud for enhanced production speed. The region faces evolving and sophisticated cyber threats, including ransomware, ad fraud malware, and DDoS attacks. Vulnerable countries such as India, Australia, Japan, China, and South Korea are focusing on robust defense infrastructure amidst increasing cyber warfare.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=220634996

Unique Features in the Artificial Intelligence in Cybersecurity Market

IoT Integration: The widespread adoption of the Internet of Things (IoT) and the growing number of connected devices are pivotal in driving market demand for AI cybersecurity.

Cyber Threats and Data Protection: The increasing frequency and sophistication of cyberattacks, along with growing concerns about data security, make AI-powered solutions more attractive.

Wi-Fi Security Vulnerabilities: The heightened risks associated with Wi-Fi networks and their increased vulnerability to breaches are also fueling the need for advanced AI-driven cybersecurity solutions.

Cloud-Based Security: The rise in demand for cloud-based cybersecurity solutions, especially among Small and Medium Enterprises (SMEs), presents significant growth opportunities for AI technologies in the sector.

Social Media Integration: As businesses increasingly rely on social media for operations, there is a growing need for AI-based cybersecurity measures to protect sensitive data and digital assets.

Limitations of AI: AI has inherent limitations in addressing zero-day vulnerabilities and advanced persistent threats, which poses a challenge for its widespread adoption in the cybersecurity field.

Insider Threats: The rise of insider threats complicates cybersecurity efforts, making it more challenging for AI technologies to safeguard data and networks.

Major Highlights of the Artificial Intelligence in Cybersecurity Market

Integration of IoT and Connected Devices: The rising integration of the Internet of Things (IoT) and the continuous growth in connected devices are major contributors to the increased need for AI-driven cybersecurity solutions.

Increase in Cyber Threats: The growing frequency of cyberattacks, coupled with heightened concerns over data privacy and security, is accelerating the demand for AI-based security tools.

Wi-Fi Network Vulnerabilities: The increasing vulnerability of Wi-Fi networks to cyber breaches has significantly boosted the demand for AI technologies to safeguard these critical infrastructure components.

Cloud-Based Security Solutions for SMEs: The demand for AI-powered, cloud-based security solutions among Small and Medium Enterprises (SMEs) is growing, creating new business opportunities in the AI cybersecurity sector.

Business Operations and Social Media: With the increasing use of social media in business operations, businesses are looking for AI-driven solutions to protect sensitive data and digital assets from cyber threats.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=220634996

Top Companies in the Artificial Intelligence in Cybersecurity Market

Major vendors in the global AI in Cybersecurity market NVIDIA (US), Intel (US), Xilinx Inc. (US), Samsung Electronics Co., Ltd (South Korea), Micron Technology, Inc. (US), IBM Corporation (US), Amazon Web Services, Inc. (US), Microsoft (US), Palo Alto Networks Inc. (US), Trellix (US), CrowdStrike (US), NortonLifeLock (US), Cylance Inc. (US), ThreatMetrix Inc. (US), Securonix Inc. (US), Sift Science (US), Acalvio Technologies (US), Darktrace (UK), SparkCognition Inc. (US), Fortinet (US), Check Point Software Technologies, Ltd (US), High-Tech Bridge (Switzerland), Deep Instinct (US), SentinelOne (US), Feedzai (US), Vectra (US) Zimperium (US), Argus Cyber Security (Israel), Nozomi Networks (US), BitSight Technologies (US), and Antivirus companies such as Kaspersky Lab (Russia), Bitdefender (Romania), and ESET (US).

NVIDIA, originally focused on PC graphics, has evolved into a key player in GPU development, delivering value across PC, mobile, and cloud architectures. The company’s emphasis has shifted towards machine learning and diverse AI technologies. Its operations are structured into two main segments: Graphics and Compute & Networking. In the Graphics segment, NVIDIA offers a range of products, including GeForce, Quadro, GeForce NOW, Tesla, and GRID, catering to visual computing in applications such as PC gaming, computer-aided design, and video editing. Professional visualization is addressed through innovations like Quadro Virtual Data Center Workstation, Project Holodeck, and NVIDIA Optix 5.0. The Compute & Networking segment provides Tegra, DRIVE PX, and SHIELD products. Tegra processors, designed for high performance, power DRIVE and SHIELD platforms. DRIVE PX processors are instrumental in automotive computers for self-driving capabilities, while SHIELD processors find applications in mobile cloud gaming. NVIDIA strategically targets gaming, professional visualization, data centre, and automotive markets. With a global presence spanning more than 40 offices across the Americas, Asia, and Europe, the company extends its reach through subsidiaries like ADEIA Technologies Switzerland AG, Icera Canada ULC, NVIDIA Brasil Computação Visual Limitada, NVIDIA Development UK Limited, NVIDIA Entertainment Devices Co., Ltd., NVIDIA Graphics Private Limited, and NVIDIA GmbH.

CrowdStrike operates as a leading provider of endpoint security solutions, anchored by its platform, CrowdStrike Falcon. This cloud-native endpoint protection platform integrates antivirus, threat intelligence, endpoint detection and response (EDR), device control, threat hunting, IT hygiene products, incident response, and proactive services. With a SaaS subscription-based model, CrowdStrike Falcon incorporates 22 cloud modules, catering to markets such as corporate workload security, security and vulnerability management, managed security services, IT operations management, threat intelligence services, identity protection, and log management. Revenue for CrowdStrike is categorized into two segments: Subscription and Professional Services. Subscription revenue is derived from Falcon platform fees and additional cloud modules, driven by factors like the number of subscription customers, endpoints per customer, and included cloud modules. On the other hand, Professional Services revenue encompasses incident response, proactive services, forensic and malware analysis, and attribution analysis. CrowdStrike serves diverse sectors, including public and retail, healthcare, and financial industries. The company’s comprehensive approach to endpoint security positions it as a key player in the rapidly evolving landscape of cybersecurity.

Intel is a global technology company specializing in the design and manufacturing of products powering the cloud and connected world. It supplies computers, networking, and communication platforms to OEMs, ODMs, cloud providers, and various industries. With business segments like Client Computing, Data Center, IoT, Memory Solutions, Programmable Solutions, and Others, Intel covers a broad spectrum of markets. In the Internet of Things Group (IOTG), Intel holds a robust position, offering components and software for diverse IoT segments like retail, transportation, industrial, and smart cities. The company’s expansion in cloud, data center, IoT, memory, and FPGA contributes to overall growth. Intel is strategically positioned in the AI landscape, reinforced by acquisitions like Saffron Technologies and Nervana Systems. The Intel Nervana AI Academy fosters AI accessibility through data, tools, and training initiatives. With a presence in over 63 countries and consumers in 120 countries, Intel continues to drive innovation and connectivity globally. Key subsidiaries include Intel Americas, Intel Asia Holding, Intel (UK), Intel Israel Holdings, Intel Kabushiki Kaisha, Intel Mobile Communications, and Intel Semiconductor (Dalian).

Darktrace is a UK-based cybersecurity company founded in 2013. It specializes in artificial intelligence for cyber defense. The company’s technology, known as the Enterprise Immune System, uses machine learning and AI algorithms to detect and respond to cyber threats in real-time. Darktrace’s solutions are designed to identify unusual activity within a network, thereby providing early warnings of potential breaches. The company has gained recognition for its innovative approach to cybersecurity and serves a broad range of industries worldwide.

High-Tech Bridge is a Switzerland-based cybersecurity company founded in 2007. It specializes in web security testing and ethical hacking. The company is known for its ImmuniWeb platform, which combines AI and human expertise to conduct comprehensive security assessments, including web and mobile application testing, and compliance monitoring. High-Tech Bridge emphasizes the importance of proactive security measures and has received recognition for its innovative solutions in the cybersecurity industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-ai-cyber-security-market-220634996.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Artificial Intelligence in Cybersecurity Market Recent Trends, Outlook, Size, Share, Top Companies, Industry Analysis, Future Development & Forecast – 2028

COPD Clinical Trials Pipeline 2025: COPD FDA Approvals, Therapy Innovations, and Emerging Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regenerative Medicine

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Chronic Obstructive Pulmonary Disease Pipeline Insight, 2025 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

 

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.

  • Chronic Obstructive Pulmonary Disease companies working in the treatment market are AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment

  • Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.

  • In April 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for asthma and chronic obstructive pulmonary disease (COPD), has received encouraging feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), specifically the Division of Pulmonology, Allergy, and Critical Care within the Office of Immunology and Inflammation.

  • In March 2025, SMSbiotech achieved a major milestone in advancing its regenerative medicine platform, receiving approval to initiate a Phase I clinical trial in Australia (registration number: ANZCTR12624001140549p). The trial aims to assess the safety and tolerability of the company’s novel Small Mobile stem (SMS) cell therapy for treating Chronic Obstructive Pulmonary Disease (COPD).

  • In January 2025, Aer Therapeutics (“Aer”), a biopharmaceutical company focused on developing innovative inhaled therapies for mucus-related lung diseases, announced that the first patient has been dosed in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (previously known as AER-01) for Chronic Obstructive Pulmonary Disease (COPD).

  • In September 2024, GSK’s asthma drug Nucala (mepolizumab) achieved its primary endpoint in a Phase III trial for treating patients with chronic obstructive pulmonary disease (COPD). Results from the MATINEE study revealed that adding Nucala to inhaled maintenance therapy significantly lowered the annualized rate of moderate or severe exacerbations compared to placebo.

  • In January 2024, Theravance Biopharma, Inc. (NASDAQ: TBPH) has released findings from the Phase 4 PIFR-2 trial of YUPELRI® (revefenacin) inhalation solution, the sole once-daily, nebulized long-acting muscarinic antagonist (LAMA) authorized in the U.S. for COPD maintenance therapy. The PIFR-2 study aimed to illustrate superior lung function enhancement with YUPELRI administered via standard jet nebulizer versus Spiriva® (tiotropium) delivered through a dry powder inhaler (Spiriva® HandiHaler®) in severe to very severe COPD patients with suboptimal peak inspiratory flow rate (PIFR).

  • In April 2024, Amgen (NASDAQ: AMGN) shared an update on the Phase 2a COURSE trial results for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which will be presented at the American Thoracic Society (ATS) 2024 International Conference. The trial, which investigated tezepelumab in patients with moderate to very severe COPD across various eosinophil levels and inflammatory drivers, showed promising results. The study did not exclude patients based on baseline eosinophil count (BEC) and enrolled a diverse group. Tezepelumab reduced the annualized rate of moderate or severe COPD exacerbations by 17% compared to placebo, though the result did not reach statistical significance.

 

Chronic Obstructive Pulmonary Disease Overview

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes breathing difficulties due to airflow obstruction. It encompasses conditions such as chronic bronchitis and emphysema, primarily resulting from long-term exposure to irritants like cigarette smoke, air pollution, and occupational dust. Symptoms include persistent cough, mucus production, wheezing, and shortness of breath, especially during physical activity. COPD is characterized by its chronic nature, often leading to worsening lung function over time. While there is no cure, management options include medications, pulmonary rehabilitation, and lifestyle changes, such as smoking cessation, to improve quality of life and reduce symptoms.

 

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight

 

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:

  • Benralizumab: AstraZeneca

  • Dupilumab: Sanofi

  • Tezepelumab: Amgen

  • SNG001: Synairgen

  • GSK3923868: GlaxoSmithKline

  • Ensifentrine: Verona Pharma

  • SAR440340: Regeneron Pharma

  • CHF 6001: Chiesi Farmaceutici S.p.A

  • QBW-251: Novartis

  • Tezepelumab: AstraZeneca

  • Anti-ST2: Genentech

  • PBF-680: Palobiofarma

  • PUR1800: Pulamtrix

 

Chronic Obstructive Pulmonary Disease Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Intramuscular

 

Chronic Obstructive Pulmonary Disease Molecule Type

Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

 

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment

  • Chronic Obstructive Pulmonary Disease Assessment by Product Type

  • Chronic Obstructive Pulmonary Disease By Stage and Product Type

  • Chronic Obstructive Pulmonary Disease Assessment by Route of Administration

  • Chronic Obstructive Pulmonary Disease By Stage and Route of Administration

  • Chronic Obstructive Pulmonary Disease Assessment by Molecule Type

  • Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

 

DelveInsight’s Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies

 

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:

Key companies developing therapies for Chronic Obstructive Pulmonary Disease are – Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Tetherex Pharmaceuticals, Verona Pharma, Vertex Pharmaceuticals, and several others.

 

Chronic Obstructive Pulmonary Disease Pipeline Analysis:

The Chronic Obstructive Pulmonary Disease pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.

  • Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies

 

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers

  • Rising disease burden associated with COPD, increasing focus on therapy development, favorable insurance coverage for COPD treatment are some of the important factors that are fueling the Chronic Obstructive Pulmonary Disease Market.

 

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers

  • However, concerns regarding the long term use of current ICS/LABA inhalers, poor regimen adherence by patients, treatment costs and other factors are creating obstacles in the Chronic Obstructive Pulmonary Disease Market growth.

 

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight

  • Coverage: Global

  • Key Chronic Obstructive Pulmonary Disease Companies: AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others

  • Key Chronic Obstructive Pulmonary Disease Therapies: Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others

  • Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies

  • Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

 

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Obstructive Pulmonary Disease Report Introduction

2. Chronic Obstructive Pulmonary Disease Executive Summary

3. Chronic Obstructive Pulmonary Disease Overview

4. Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Obstructive Pulmonary Disease Pipeline Therapeutics

6. Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)

7. Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)

8. Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)

9. Chronic Obstructive Pulmonary Disease Preclinical Stage Products

10. Chronic Obstructive Pulmonary Disease Therapeutics Assessment

11. Chronic Obstructive Pulmonary Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Obstructive Pulmonary Disease Key Companies

14. Chronic Obstructive Pulmonary Disease Key Products

15. Chronic Obstructive Pulmonary Disease Unmet Needs

16 . Chronic Obstructive Pulmonary Disease Market Drivers and Barriers

17. Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion

18. Chronic Obstructive Pulmonary Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COPD Clinical Trials Pipeline 2025: COPD FDA Approvals, Therapy Innovations, and Emerging Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regenerative Medicine